Cost-Effectiveness of SelectMDx in Prostate Cancer Risk Assessment

In this study, we sought to characterize the cost-effectiveness of SelectMDx in a population of U.S. men with elevated PSA.

Source: The Journal of Urology - July 15, 2018 Category: Urology & Nephrology Authors: Tim Govers, Laura Caba, Matthew J. Resnick Source Type: research